Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMP360 in Treatment-Resistant Depression
NCT05624268Phase 3Completed
- Sponsor
- COMPASS Pathways
- Start
- Jan 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in treatment-resistant depression (TRD) comparing 25 mg COMP360 Psilocybin with Placebo (2 arms). Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 6 weeks. Started Jan 2023; status: completed.
02
Drugs
COMP360
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05624268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05624268.